Tesamorelin vs GHRP-2
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Egrifta, Egrifta WR
An FDA-approved GHRH analog used to reduce excess abdominal fat in HIV-infected patients with lipodystrophy. New F8 formulation (Egrifta WR) approved March 2025 allows weekly reconstitution vs daily.
Also: Growth Hormone Releasing Peptide 2, Pralmorelin
A synthetic hexapeptide that potently stimulates GH release. More potent than GHRP-6 with less appetite stimulation, but still elevates cortisol and prolactin.
Key Comparison Insights
- Tesamorelin is FDA approved, while GHRP-2 remains in research stages.
- Both peptides belong to the Growth Hormone category, suggesting similar primary applications.
- Tesamorelin has stronger research evidence (FDA Approved) compared to GHRP-2 (Human Trials).
Detailed Comparison
| Attribute | Tesamorelin | GHRP-2 |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| FDA Status | FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Tesamorelin is a stabilized analog of human GHRH that stimulates the pituitary to release growth hormone. It specifically reduces visceral adipose tissue (VAT) while having minimal effect on subcutaneous fat, likely through GH-mediated lipolysis. | GHRP-2 acts on ghrelin receptors to stimulate GH release from the pituitary. It has the strongest GH-releasing effect among GHRPs but also causes more cortisol and prolactin release than ipamorelin. Less appetite stimulation than GHRP-6. |
| Common Dosing | 2 mg daily (F8: 1.28 mg daily) Once daily | 100-300 mcg 2-3x daily 2-3x daily |
| Administration | Subcutaneous injection | Subcutaneous injection |
| Typical Duration | Indefinite for approved indication | 8-12 weeks |
| Best Time to Take | Before bed (fasted) | Before bed or morning (fasted) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | FDA approved based on trials showing 15-20% reduction in visceral adipose tissue over 26 weeks. March 2025: FDA approved new F8 formulation (Egrifta WR) with weekly reconstitution, reducing patient burden. CROI 2025 data highlighted limitations of BMI for cardiovascular risk assessment in HIV patients. | Studies show it produces the highest GH release among common GHRPs. Research demonstrates reliable diagnostic use for GH deficiency testing. Animal studies show improved muscle mass and recovery. |
Frequently Asked Questions: Tesamorelin vs GHRP-2
What is the difference between Tesamorelin and GHRP-2?
Tesamorelin is a growth hormone peptide that an fda-approved ghrh analog used to reduce excess abdominal fat in hiv-infected patients with lipodystrophy. new f8 formulation (egrifta wr) approved march 2025 allows weekly reconstitution vs daily. GHRP-2 is a growth hormone peptide that a synthetic hexapeptide that potently stimulates gh release. more potent than ghrp-6 with less appetite stimulation, but still elevates cortisol and prolactin. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Tesamorelin or GHRP-2?
Neither is universally "better" - the choice depends on your specific goals. Tesamorelin is typically used for growth hormone purposes, while GHRP-2 is used for growth hormone. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Tesamorelin and GHRP-2 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Tesamorelin and GHRP-2 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.